Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 39 in last 24h · 115,255 total before filter · latest 2h ago
39last 24h
1802last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
AllMacro322Earnings851M&A104Regulatory25Product16Analyst25
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
JD.com (JD) Faces 618 False Advertising Probe As Investor Lawsuit Risk Builds
Simply Wall St.35d agobearish
JD.com (JD) Faces 618 False Advertising Probe As Investor Lawsuit Risk Builds

Chinese regulators have summoned JD.com over alleged false advertising during the recent 618 shopping festival. The scrutiny centers on how promotional offers and discounts were presented during one of China's key mid year sales events. Law firm Pomerantz LLP has launched a securities fraud investigation linked to this regulatory action on behalf of JD.com investors. JD.com, listed on the NasdaqGS under the ticker NasdaqGS:JD, now sits in the spotlight as regulators and investors assess the...

Meta business model in trouble from $1.4 trillion lawsuit
TheStreet37d agobearish
Meta business model in trouble from $1.4 trillion lawsuit

If you have ever caught yourself doom scrolling on Instagram or Facebook for hours on end and felt bad, don't; the technology is working exactly how it was intended to. Everything from the length and style of the Reels to the algorithms' encyclopedic knowledge of your likes and dislikes is designed ...

Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus
Simply Wall St.38d agobearish
Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus

Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...

Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit
Yahoo Finance Video39d agobearishVIDEO
Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit

Market Domination Host Josh Lipton tracks several of the day's top trending stock tickers, including JPMorgan analysts raising their price target on Eli Lilly (LLY) stock, Vertex Pharmaceuticals' (VRTX) acquisition of Crinetics (CRNX), and the possible $1.4 trillion lawsuit that multiple states are now suing Meta Platforms (META) for.

Bloomberg39d agobearish
China Watchdog Monitoring US Lawsuit Over Insider Trading Claims

(Bloomberg) -- China’s securities regulator said it was monitoring developments in a US lawsuit after Susquehanna International Group alleged insider traders made at least $100 million from well-timed options bets before Beijing’s recent crackdown on illegal cross-border trading. Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaMicrosoft’s Xbox to Cut 3,200 Jobs, Divest Five Studios in Major OverhaulTwo Millennium Trading Pods Made About $3.7 Billion Last M

Google Loses EU Antitrust Fight; Softbank Moves on Computing Power | Stock Movers
Bloomberg44d agoneutralVIDEO
Google Loses EU Antitrust Fight; Softbank Moves on Computing Power | Stock Movers

On this episode of Stock Movers: - SoftBank (SFTBY) shares are responding to news that it is starting a new U.S. venture to rent out the computing power needed to build and run artificial-intelligence models, aiming to capitalize on strong American demand for AI computing resources. - Shares of Alphabet/Google (GOOG) are responding to the company losing its long-running fight against a 4.1 billion ($4.7 billion) European Union antitrust fine after the bloc's top judges said regulators were right to punish the US giant for abusing Android's market power.

Top EU court dismisses Google appeal of $4.5 billion antitrust fine
Associated Press44d agobearish
Top EU court dismisses Google appeal of $4.5 billion antitrust fine

Judges at the European Union's top court dismissed an appeal by Google over a landmark, 4.1 billion euro ($4.5 billion) antitrust fine imposed for throttling competition and reducing consumer choice through the dominance of its mobile Android operating system. The case has been tangled up in courts since the European Commission announced the fine in 2018. “The appeal brought by Google and its parent company Alphabet against the judgment of the General Court is dismissed, thereby confirming the penalty imposed for Google Search’s abuse of a dominant position in the context of the Android operating system,” the Luxembourg-based judges wrote in their ruling.

Google loses fight against record €4.1 billion EU antitrust fine
Reuters44d agoneutral
Google loses fight against record €4.1 billion EU antitrust fine

Alphabet's Google on Thursday lost its fight against a record fine imposed by ‌EU antitrust regulators eight years ago for using its Android mobile operating ‌system to block rivals, a court ruling likely to boost Europe's crackdown on Big Tech. The European ​Commission had originally handed out a €4.34 billion fine to Google in 2018 for its agreements which forced phone manufacturers to pre-install Google Search, the Chrome browser and the Google Play app store on their Android devices and prevented them from using rival ‌Android systems. Google then appealed ⁠to the Luxembourg-based Court of Justice of the European Union, Europe's highest.